Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,051 recruiting studies in this area right now.
By phase
- Not applicable2,997
- Phase 21,057
- Phase 1792
- Phase 1/Phase 2437
- Phase 3436
- Phase 4234
- Phase 2/Phase 398
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma327
- Asthma193
- Lymphoma178
- Rheumatoid Arthritis132
- Type 1 Diabetes130
- Atopic Dermatitis125
- Systemic Lupus Erythematosus119
- Acute Lymphoblastic Leukemia118
- HIV Infections106
- Chronic Lymphocytic Leukemia95
- Autoimmune Diseases77
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Diabetes Mellitus, Type 163
- Hodgkin Lymphoma63
- Leukemia63
- Mantle Cell Lymphoma62
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca63
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic49
- City of Hope Medical Center48
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California496
- Maryland200
- Alabama178
- Florida149
- Arizona147
- Massachusetts116
- New York116
- Texas112
- Illinois83
- Colorado82
Recruiting studies6,051 total
- NCT05678621RecruitingPhase 2/Phase 3
Testing stopping or extending immune treatment to prevent infections
This trial studies whether people with certain blood cancers can safely stop their immune support medicine (immunoglobulin, also called Ig) or whether they should continue. It also tests antibiotic prevention strategies to reduce the risk of serious infections.
Garran, Australian Capital TerritoryAges 18 years+ - NCT06376214Recruiting
Daratumumab for newly diagnosed light chain amyloidosis
This trial tests the drug daratumumab in people newly diagnosed with light chain amyloidosis that affects the heart, kidney, or liver. The goal is to see if daratumumab can help control the disease. Eligibility depends on your disease stage and overall health.
Nanjing, JiangsuAges 18–75 - NCT06376721RecruitingPhase 1/Phase 2
Linperlisib combo for advanced NK/T-cell lymphoma
This trial tests a combination of three drugs (linperlisib, camrelizumab, and pegaspargase) for people with a rare type of lymphoma called ENKTL. It is for patients whose cancer has not responded to treatment or has come back, or who are newly diagnosed with advanced disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT06382987Recruiting
Comparing deucravacitinib vs apremilast for plaque psoriasis
This study compares two oral medications, deucravacitinib and apremilast, for adults with plaque psoriasis in Japan. It looks at how well each drug works in real-world use.
Minato-ku, TokyoAges 18 years+ - NCT04565483RecruitingPhase 4
Test a blood-test signature to predict benralizumab benefit
This trial studies whether a specific “signature” from asthma tests can predict who will respond to benralizumab (a severe asthma biologic). If you qualify, the researchers will compare your test results to how well benralizumab controls your asthma and prevents flare-ups.
Aix-en-ProvenceAges 18–75 - NCT01965132Recruiting
Biologic and targeted therapy registry for arthritis patients
This registry is collecting information about people with rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis who are starting or needing biologic or targeted medicines. It may help researchers better understand how these treatments work in real life.
SeoulAges 18 years+ - NCT06381817RecruitingPhase 3
Stem cell transplant comparison for T-cell leukemia
This study compares two types of stem cell transplants for adults with T-ALL: one using a half-matched donor alone, and one using a half-matched donor plus umbilical cord blood. The goal is to see which approach gives better results with fewer side effects.
Suzhou, JiangsuAges Any age - NCT06391190RecruitingPhase 1/Phase 2
Chemoradiation plus immunotherapy for advanced cervical cancer
This trial tests combining standard chemoradiation with a PD-1 inhibitor (a drug that helps your immune system fight cancer) for advanced cervical cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatment alone.
ShanghaiAges 18–75 - NCT06390696Recruiting
Sand play for eczema: a biodiversity study
This study looks at whether playing in sand with different types of natural materials (to increase your contact with harmless microbes) can improve eczema symptoms. You would stop using your usual eczema creams during the trial to see if the sand play alone helps.
Helsinki, UusimaaAges 2–5 - NCT06037967Recruiting
Studying biomarkers for allergies, asthma, and mast cell disorders
This trial collects blood and tissue samples to better understand allergies, asthma, and mast cell conditions. It aims to find markers that could improve diagnosis and treatment. Participation involves donating samples and sharing medical history.
ToulouseAges 18–100 - NCT05790330Recruiting
Study brain–skin links in teenagers with eczema
This study looks at how eczema may be connected to the brain and sleep, using questionnaires and MRI scans. It may help researchers understand what drives symptoms and how treatments could be improved.
LondonAges 12–18 - NCT06149910Recruiting
Study of Treatment Plans for Newly Diagnosed Multiple Myeloma
This study looks at whether a new treatment plan (called a clinical pathway) helps doctors make better decisions for people just diagnosed with multiple myeloma. It will review medical records and may ask you to use a secure online platform to share your health information.
Seattle, WashingtonAges 18 years+ - NCT06397677Recruiting
Study of Progressive RA Interstitial Lung Disease
This study is looking at people with rheumatoid arthritis (RA) who also have interstitial lung disease (ILD), a condition that causes scarring in the lungs. It aims to understand how the disease changes over time by using imaging and blood tests, without providing any new treatments right now.
San Francisco, CaliforniaAges 18–90 - NCT05510323RecruitingPhase 3
Immunosuppressive treatment for IgA kidney disease in stage 3–4
This trial tests whether immunosuppressive therapy (medicine that calms the immune system) helps people with IgA nephropathy and moderately to severely reduced kidney function. It is intended for adults with confirmed IgA kidney disease who still have significant protein in the urine despite standard blood-pressure kidney protection treatment.
Xi'anAges 18 years+ - NCT05132179Recruiting
Testing two antiseptic creams for diabetic foot ulcers
This study compares two topical (applied on the skin) antimicrobial agents—Dakin’s and Prontosan—to help heal diabetic foot ulcers. You may be eligible if you have a diabetic foot ulcer that has been present for at least 3 weeks and is large enough.
Uddevalla, TrollhattanAges 18–100 - NCT05832515RecruitingPhase 1
Stem cell transplant for multiple sclerosis with MS-prep chemotherapy
This early-phase study tests a stem cell transplant procedure for people with multiple sclerosis whose usual MS medicines have not worked or can’t be tolerated. The goal is to see if this approach can help control MS activity and progression, while checking for safety.
Saint PetersburgAges 18–65 - NCT05496582Recruiting
Study genes linked to asthma using a lab-based approach
This trial looks at how certain proteins (Transgelin-2, Metallothionein-2, and Ezrin) are associated with asthma. It may help researchers better understand asthma biology and potentially guide future treatments.
Changsha, HunanAges 14–75 - NCT06279065Recruiting
Gut bacteria and giant cell arteritis study
This trial looks at how the bacteria in your gut might affect giant cell arteritis, a condition that causes inflammation in blood vessels. It aims to help doctors better understand the disease.
Bonn, North Rhine-WestphaliaAges 18 years+ - NCT06002659RecruitingPhase 1/Phase 2
CAR T therapy targeting CD20 for B-cell lymphoma
This study tests a new type of CAR T cell therapy that targets the CD20 protein on B-cell lymphoma cells. It is for people with certain types of B-cell lymphoma that have not responded to at least two previous treatments and who cannot use or have already tried the approved CD19 CAR T therapy.
StockholmAges Any age - NCT06405997Recruiting
Study of LAM: genes and symptoms
This study looks at the genes and physical traits of people with lymphangioleiomyomatosis (LAM), a rare lung disease that causes cysts. It aims to help better understand and treat LAM.
TaipeiAges 18 years+ - NCT04061512RecruitingPhase 2/Phase 3
Rituximab plus ibrutinib versus standard steroids plus rituximab
This trial compares two starting treatment plans for Waldenström’s macroglobulinaemia, testing whether one works better or causes fewer problems. It studies rituximab plus ibrutinib versus a standard mix of rituximab, cyclophosphamide, and dexamethasone (steroids).
BathAges 18 years+ - NCT06406205RecruitingPhase 3
Study of QLG1074 for active lupus nephritis
This trial tests a new medicine called QLG1074 added to standard treatments for people with active lupus nephritis, a kidney problem caused by lupus. It aims to see if the combination helps control the disease better.
Bengbu, AnhuiAges 18–75 - NCT03981003Recruiting
Blood tests to track brain and nerve changes in MS
This study measures blood markers (from a serum blood sample) to see how nerve and brain changes relate to MS disease activity and disability over time. It may help researchers better monitor MS, especially in people followed in the OFSEP program.
AmiensAges 15 years+ - NCT04933552Recruiting
Safety study of Mayzent during pregnancy for babies
This study follows pregnant people with multiple sclerosis (MS) who took Mayzent (siponimod) to understand safety for pregnancy outcomes. It compares them with other groups to see whether there are any differences in birth results.
La Jolla, CaliforniaAges Any age
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,051 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,083 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.